Labiotech.eu

News and Trends 29 Jul 2015

How to create a late-stage Biotech company in record time? Ask Novartis!

Mereo BioPharma. This name doesn’t ring a bell? From now on, you should keep it in mind as it could rapidly become a rising star on the European Biotech scene. Launched five months ago, the company has already three candidates in phase II and just raised $119m (approximately €108m) from private investors! Mereo has everything […]

July 29, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 29 Jul 2015

Erytech follows the path of DBV and Cellectis into the US stock exchange

Erytech Pharma, developer of an innovative ‘tumor starvation’ treatment, today announced that it plans to conduct a registered initial public offering in the United States and thus, plays in the major league with its French fellows DBV and Cellectis. It’s definitely the last trend in Biotech! European companies are queuing up to enter the US stock market. In […]

July 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 29 Jul 2015

Effective Antibody from a Patient recovering from Middle East Respiratory Syndrome

Two months after the outbreak of the coronavirus in South Korea, researchers are presenting first results of an effective treatment for the Middle East Respiratory Syndrome (MERS). The Swiss biotech Humabs BioMed has been able to isolate an effective antibody from a cured patient that should now be further developed under a non-profit base. In 2012, […]

July 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 28 Jul 2015

We met Antoine Hubert, CEO of Ynsect and awarded Innovator Under 35 by the MIT

Each year since 1999, MIT Technology Review, the journal from the top-rank US University, discovers new generations of Innovators Under 35. The awarded young leaders are developing new technologies to solve the major global challenges of today in remarkably different ways and impacting the lives of millions of people around the globe. We had the […]

July 28, 2015 - 7 minutesmins - By Marie Godar

News and Trends 28 Jul 2015

Struggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M

The Pharma giant AstraZeneca is still struggling even if in better shape. It just sold one of his rare disease drug already on the market to THE rare disease Biotech Genzyme, now part of Sanofi. AstraZeneca is under pressure. Last April 2015, the company reported a fall in revenues and profits (7% lower than previous […]

July 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 Jul 2015

Allergan Continues its Serial Acquisitions to be a Giant Drugmaker

With Allergan’s absorption by Actavis last year, we ask ourselves, will the newly formed company enter the World’s Top Ten drugmaker companies worldwide? And it has been very active indeed, expanding its portfolio with several acquisitions. Allergan’s buyout fever is not finished as the company just announced the acquisition of Naurex! It was in mars 2015, when Actavis completed […]

July 28, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Using camel antibodies as drugs, sounds crazy? Belgian Ablynx is exactly doing that and has been very successful so far. It’s now moving to the next step. It already signed a €1.7Bn deal with Merck & Co. in February 2014 and now upgrades it to a gigantic €5.7Bn! Ablynx is a biotech company developing Nanobodies for immune-oncology […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Roche exits €940M discovery alliance with Molecular Partners

Roche left the collaboration with Molecular Partners, walking away from a potential cancer treatment using the DARPin technology. The collaboration, entered in 2013, was worth up to €940M. Molecular Partners is a Swiss company focusing on immuno-oncology. The company has developed a platform generating small proteins called DARPins (Designed Ankyrin Repeat Proteins). These can target […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans? Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 26 Jul 2015

Roche’s Deal pushes Vifor’s split from Galenica

Switzerland’s biggest pharmacy network, Galenica, wants to split off the specialty pharma company Vifor Pharma. This could be done earlier than expected, thanks to a lucrative Roche deal. Galenica has made large investments in the pharma business over the recent years. Vifor Pharma is already a world leader when it comes to iron deficiency treatments. In […]

July 26, 2015 - 1 minutemin - By Philip Hemme

News and Trends 24 Jul 2015

MGB puts a new spin on fighting multi-resistant bacteria

MGB Biopharma wants to tackle multi-resistant bacteria with their newly developed anti-infectives. Its lead candidate, MGB-BP-3 is now entering Phase I. Biotech companies use several approaches when it comes to killing bacteria, especially when these are resistant against antibiotics. In our last news, we have seen, Ferring betting on bacteriophages or ELIGO using CRISPR on this purpose. The Scottish […]

July 24, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

MorphoSys’ blood disorder antibody reaches Phase I

MorphoSys AG seems to be sitting on a goldmine with its Human Combinatorial Antibody Library (HuCAL). The German giant snatched the second milestone payment from Novartis this year. The latter will now initiate a Phase I test for a HuCAL antibody designed to treat blood disorders. MorphoSys landed some big accounts in the past. Pfizer, Bayer, […]

July 23, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

How to create a late-stage Biotech company in record time? Ask Novartis!

Erytech follows the path of DBV and Cellectis into the US stock exchange

Effective Antibody from a Patient recovering from Middle East Respiratory Syndrome

We met Antoine Hubert, CEO of Ynsect and awarded Innovator Under 35 by the MIT

Struggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M

Allergan Continues its Serial Acquisitions to be a Giant Drugmaker

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Roche exits €940M discovery alliance with Molecular Partners

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Roche’s Deal pushes Vifor’s split from Galenica

MGB puts a new spin on fighting multi-resistant bacteria

MorphoSys’ blood disorder antibody reaches Phase I

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!